By Counterforce Health Team in Fabrazyme (agalsidase beta) —

How to Get Fabrazyme (agalsidase beta) Covered by UnitedHealthcare in Texas: Prior Authorization, Appeals, and Alternative Paths

Answer Box: Getting Fabrazyme Covered by UnitedHealthcare in Texas

UnitedHealthcare requires prior authorization for Fabrazyme (agalsidase beta) with 12-month approvals based on confirmed Fabry disease diagnosis, genetic testing, and treatment response documentation. Fastest path: Submit PA through OptumRx with specialist letter, recent labs, and genetic confirmation 30 days before needed. If denied, Texas allows internal appeals within 180 days followed by independent external review through Texas Department of Insurance within 4 months.

First step today: Contact your prescribing specialist to gather genetic testing results, recent clinical notes, and lab values for PA submission.

Table of Contents

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all Fabrazyme prescriptions OptumRx formulary documents UnitedHealthcare Provider Portal
Formulary Tier Tier 4 (Medicare), Tier 3 (Retiree plans) Plan-specific formulary OptumRx Formularies
Genetic Testing GLA gene sequencing required Lab reports from certified facilities UnitedHealthcare ERT Policy
Specialist Prescriber Metabolic or genetic specialist typically required Provider credentials verification UnitedHealthcare PA forms
Adherence Documentation ≥85% compliance with therapy Pharmacy fill history OptumRx system
Appeals Deadline (Texas) 180 days from denial for internal appeal Denial letter instructions Texas Department of Insurance

When Alternatives Make Sense

UnitedHealthcare may initially deny Fabrazyme and suggest alternatives, particularly if you haven't tried other treatments or if your genetic testing shows specific mutation types. Understanding when alternatives are medically appropriate—versus when an exception is warranted—can save time and prevent unnecessary delays.

Alternatives make clinical sense when:

  • Your GLA mutation is amenable to oral chaperone therapy (migalastat/Galafold)
  • You're new to Fabry treatment and haven't tried first-line options
  • Previous enzyme replacement therapy caused severe infusion reactions
  • You have contraindications to IV therapy or poor venous access

Fabrazyme exception is warranted when:

  • Your mutation is non-amenable to migalastat (about 50-65% of patients)
  • You've failed or shown intolerance to Galafold
  • You have severe kidney disease (eGFR <30) where migalastat is contraindicated
  • You're under 18 years old (migalastat not approved for pediatric use)
Note: Counterforce Health specializes in turning insurance denials into targeted appeals by analyzing your specific plan policy and crafting evidence-backed rebuttals that align with your insurer's own coverage rules.

Typical Formulary Alternatives

UnitedHealthcare's OptumRx formularies list several alternatives that may be suggested before approving Fabrazyme:

Oral Chaperone Therapy

Galafold (migalastat) appears on most UnitedHealthcare formularies with prior authorization:

  • Coverage: Medicare Tier 5, Retiree Tier 3, Select plans
  • Requirements: Genetic testing confirming amenable GLA mutation
  • Dosing: 123 mg capsule every other day
  • Eligibility: About 35-50% of Fabry patients have amenable mutations

Other Enzyme Replacement Therapies

Elfabrio (pegunigalsidase alfa) is typically excluded unless required by state law but may be considered for patients with high antibody levels to other ERTs.

Step Therapy Protocols

UnitedHealthcare's 2025 enhanced utilization management includes stricter step therapy requirements. For Fabry disease, this typically means:

  1. Trial of migalastat (if mutation amenable)
  2. Documentation of failure, intolerance, or contraindication
  3. Approval for IV enzyme replacement therapy

Pros and Cons Overview

Treatment Advantages Limitations Access Considerations
Fabrazyme • Broad efficacy for all mutations
• Pediatric approval (≥2 years)
• Established safety profile		 • IV infusion every 2 weeks
• Infusion reactions (50%)
• High cost ($300K/year)		 • Requires PA
• Infusion site needed
• Prior authorization renewal annually
Galafold • Oral convenience
• No infusion reactions
• Lower treatment burden		 • Limited to amenable mutations
• Kidney function monitoring required
• Not for severe renal impairment		 • Genetic testing prerequisite
• PA required
• Quantity limits (14 capsules/28 days)

Exception Strategy

When UnitedHealthcare suggests alternatives that aren't medically appropriate for your case, a well-documented exception request is your strongest path to Fabrazyme approval.

Medical Necessity Documentation Checklist

Your specialist should include these elements in the prior authorization:

Diagnostic Confirmation:

  • Genetic testing results showing GLA mutation
  • Enzyme activity levels (for males) or family history (for females)
  • Clinical manifestations of Fabry disease

Treatment Rationale:

  • Why Fabrazyme is medically necessary for your specific case
  • Documentation of contraindications to alternatives
  • Expected treatment goals and monitoring plan

Supporting Evidence:

  • Recent laboratory results (within 6 months)
  • Cardiac evaluation (echocardiogram, ECG)
  • Kidney function assessment (eGFR, proteinuria)
  • Pain scores and quality of life measures

Key Arguments for Fabrazyme Exception

For Non-Amenable Mutations: "Patient's GLA mutation [specify] is not amenable to migalastat therapy per FDA-approved assay. Fabrazyme represents the standard of care for enzyme replacement in this population."

For Pediatric Patients: "Migalastat is not FDA-approved for patients under 18 years. Fabrazyme has established safety and efficacy in pediatric Fabry patients ≥2 years old."

For Renal Impairment: "Patient's eGFR of [value] mL/min/1.73m² contraindicates migalastat use. Fabrazyme is appropriate for patients with advanced kidney disease."

Appeals Playbook for Texas

Texas provides robust patient rights for appealing insurance denials, with specific timelines and processes that apply to UnitedHealthcare plans.

Internal Appeals Process

Timeline: File within 180 days of denial Decision Time: 30 days for pre-service requests, 60 days for post-service How to Submit: UnitedHealthcare member portal, mail, or fax (check denial letter for specific instructions)

Required Documentation:

  • Completed UnitedHealthcare appeal form
  • Copy of original denial letter
  • Medical records supporting medical necessity
  • Specialist letter of medical necessity
  • Any additional clinical evidence

Expedited Appeals

For urgent situations where delay could jeopardize your health: Timeline: 72 hours for decision Eligibility: Time-sensitive treatments, clinical deterioration risk Documentation: Physician attestation of urgency required

External Review (Texas IRO)

If internal appeals are denied, Texas law provides independent review:

Timeline: Request within 4 months of final internal denial Process: Texas Department of Insurance contracts with Independent Review Organizations Cost: Paid by the insurance company Decision Time: 20 days (5 days for urgent cases) Binding: IRO decisions are final and must be followed by the insurer

Contact Information:

  • Texas Department of Insurance: 1-800-252-3439
  • IRO Information Line: 1-866-554-4926
From our advocates: "We've seen cases where patients were initially denied Fabrazyme due to 'step therapy' requirements, but successful appeals focused on demonstrating that the patient's specific genetic mutation made oral alternatives ineffective. The key was providing genetic testing results that clearly showed non-amenable mutations, along with specialist documentation explaining why IV enzyme replacement was the only viable option."

Switching Logistics

If you're currently on an alternative treatment and need to switch to Fabrazyme, coordination between your care team and UnitedHealthcare is essential.

From Galafold to Fabrazyme

No washout period required - you can stop migalastat and start Fabrazyme at the next convenient treatment date.

Coordination Steps:

  1. Stop Galafold on the day you decide to convert
  2. Schedule first Fabrazyme infusion within 1-2 weeks
  3. Arrange infusion site with proper emergency equipment
  4. Update insurance authorization for new treatment
  5. Plan monitoring as if starting ERT for the first time

Infusion Setup Requirements

  • Healthcare facility with resuscitation equipment
  • Staff trained in Fabrazyme preparation and administration
  • Initial slow infusion rate (≤15 mg/hour) for first 8 treatments
  • Vital sign monitoring throughout infusion and 30-60 minutes post-infusion

Re-trying for Fabrazyme Later

If you initially try an alternative treatment that proves insufficient, documenting the trial properly strengthens your case for Fabrazyme approval.

Documentation During Alternative Trials

Clinical Monitoring:

  • Biomarker levels (lyso-Gb3, Gb3) every 6 months
  • Kidney function (eGFR, proteinuria) quarterly
  • Cardiac assessment (echocardiogram) annually
  • Pain and quality of life scores at each visit

Failure Documentation:

  • Objective measures showing disease progression
  • Intolerable side effects with specific examples
  • Adherence records showing compliance wasn't the issue
  • Specialist assessment confirming treatment inadequacy

When to Request Switch

Clinical Indicators:

  • Worsening kidney function despite alternative therapy
  • Progression of cardiac involvement
  • Increased pain or decreased quality of life
  • New clinical manifestations of Fabry disease

Insurance Considerations: UnitedHealthcare typically requires 6-12 months of alternative therapy trial unless contraindications exist. Counterforce Health can help analyze your plan's specific requirements and craft appeals that demonstrate why a shorter trial period is medically inappropriate for your case.

Common Questions

How long does UnitedHealthcare prior authorization take in Texas? Standard PA decisions are made within 15 business days. Expedited reviews (with physician attestation of urgency) are completed within 72 hours.

What if Fabrazyme is non-formulary on my plan? Non-formulary drugs can still be covered through medical exception requests. Your specialist must demonstrate medical necessity and why formulary alternatives are inappropriate.

Can I request an expedited appeal if my Fabrazyme is denied? Yes, if your physician certifies that delay would jeopardize your health. Expedited appeals must be decided within 72 hours.

Does step therapy apply if I've failed treatments outside Texas? Previous treatment failures from other states should be documented and submitted with your PA request. UnitedHealthcare typically accepts out-of-state medical records.

What happens if I lose my job and UnitedHealthcare coverage? COBRA allows continuation of coverage for 18-36 months. Contact Sanofi Patient Connection for potential bridge therapy assistance during coverage gaps.

How much will Fabrazyme cost with UnitedHealthcare? Costs vary by plan tier and deductible. Medicare Part D plans have a $2,000 annual out-of-pocket maximum starting in 2025. Check with Sanofi for copay assistance programs.

Disclaimer: This information is for educational purposes and does not constitute medical advice. Insurance coverage decisions depend on individual plan benefits and medical circumstances. Always consult with your healthcare provider and insurance company for guidance specific to your situation.

For additional assistance with Texas insurance appeals, contact:

  • Texas Department of Insurance: 1-800-252-3439
  • Office of Public Insurance Counsel: 1-877-611-6742
  • Disability Rights Texas (for advocacy support)

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.